AI Maverick Intel Inc. (OTCID: AIMV) has entered into a definitive share purchase agreement to acquire Heal Access Canada Inc., an artificial intelligence healthcare technology company, from its controlling stockholder, HEAL Group Holdings Inc. The transaction, valued at $5 million through a secured two-year promissory note bearing 10% annual interest plus 20 million exchangeable shares convertible into AIMV common stock, represents a strategic move to integrate an operational AI healthcare platform that currently serves more than 118,000 patients across five countries. The deal underscores the growing convergence of artificial intelligence and healthcare, a sector where data-driven clinical decision support and patient information integration are becoming critical to improving outcomes and operational efficiency.
The acquisition matters because it gives AIMV immediate access to a live, revenue-generating AI platform rather than a developmental-stage technology. Heal Access's AI-powered healthcare intelligence platform integrates patient information and supports clinical workflows, positioning AIMV to compete in the rapidly expanding market for agentic AI healthcare solutions. Upon conversion of all exchangeable shares, HEAL Group would hold approximately 80.1% of AIMV common stock before accounting for any shares issued in the financing, a concentration of ownership that could influence corporate governance and future strategic decisions. AIMV will also assume approximately $6.4 million in existing obligations owed by Heal Access and its subsidiaries to HEAL Group and affiliates, adding financial leverage to the post-closing entity.
The transaction remains subject to several closing conditions, including at least $6 million in financing and independent special committee ratification. AIMV expects to use commercially reasonable efforts to complete the required financing by Dec. 31, 2026, with either party permitted to terminate the agreement if the transaction has not closed by Feb. 28, 2027. AIMV clarified that its Sept. 21 announcement incorrectly described the acquisition agreement as definitive, noting that the binding agreement was signed Oct. 12, 2026. This correction highlights the importance of precise disclosure in public markets, particularly for OTC-quoted companies where investor confidence can be sensitive to regulatory filings and press release accuracy. For investors tracking AIMV, the definitive agreement provides greater certainty than the earlier mischaracterization, though the financing condition introduces execution risk.
The broader implications extend to the competitive landscape of AI healthcare. By acquiring Heal Access, AIMV gains a platform with proven international reach, which could accelerate its growth strategy and attract partnerships or additional acquisitions. The company has stated its intention to grow through Heal Access and through further acquisitions of AI and technology-enabled healthcare businesses, including opportunities available under its right of first refusal agreement with HEAL Group Holdings Inc. This consolidation strategy may pressure other small-cap healthcare AI firms to seek scale or differentiation. For the healthcare industry, the deal signals that AI platforms capable of integrating patient data and supporting clinical workflows are becoming attractive acquisition targets, potentially driving more investment into similar technologies. As AI continues to reshape healthcare delivery, transactions like this one illustrate how public markets are valuing operational AI assets and the strategic importance of controlling stockholder relationships. The full press release is available at https://ibn.fm/1XVOv, and ongoing updates can be found in the company's newsroom at http://ibn.fm/AIMV. The news was distributed through TechMediaWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. Investors should review the full terms of use and disclaimers at https://www.TechMediaWire.com/Disclaimer.
